Literature DB >> 14718403

Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

Noritoshi Nagaya1, Shingo Kyotani, Masaaki Uematsu, Kazuyuki Ueno, Hideo Oya, Norifumi Nakanishi, Mikiyasu Shirai, Hidezo Mori, Kunio Miyatake, Kenji Kangawa.   

Abstract

BACKGROUND: Adrenomedullin (AM) is a potent pulmonary vasodilator peptide. However, whether intratracheal delivery of aerosolized AM has beneficial effects in patients with idiopathic pulmonary arterial hypertension remains unknown. Accordingly, we investigated the effects of AM inhalation on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. METHODS AND
RESULTS: Acute hemodynamic responses to inhalation of aerosolized AM (10 microg/kg body wt) were examined in 11 patients with idiopathic pulmonary arterial hypertension during cardiac catheterization. Cardiopulmonary exercise testing was performed immediately after inhalation of aerosolized AM or placebo. The work rate was increased by 15 W/min until the symptom-limited maximum, with breath-by-breath gas analysis. Inhalation of AM produced a 13% decrease in mean pulmonary arterial pressure (54+/-3 to 47+/-3 mm Hg, P<0.05) and a 22% decrease in pulmonary vascular resistance (12.6+/-1.5 to 9.8+/-1.3 Wood units, P<0.05). However, neither systemic arterial pressure nor heart rate was altered. Inhalation of AM significantly increased peak oxygen consumption during exercise (peak o(2), 14.6+/-0.6 to 15.7+/-0.6 mL. kg(-1). min(-1), P<0.05) and the ratio of change in oxygen uptake to that in work rate (Deltao(2)/DeltaW ratio, 6.3+/-0.4 to 7.0+/-0.5 mL. min(-1). W(-1), P<0.05). These parameters remained unchanged during placebo inhalation.
CONCLUSIONS: Inhalation of AM may have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718403     DOI: 10.1161/01.CIR.0000109493.05849.14

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.

Authors:  Habib Bouzina; Göran Rådegran
Journal:  Pulm Circ       Date:  2020-06-15       Impact factor: 3.017

Review 2.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 3.  [Role of adrenomedullin in the pathogenesis and treatment of cardiovascular dysfunctions and sepsis].

Authors:  M Westphal; J Sander; H Van Aken; C Ertmer; H D Stubbe; M Booke
Journal:  Anaesthesist       Date:  2006-02       Impact factor: 1.041

Review 4.  Prostacyclin for pulmonary hypertension in adults.

Authors:  N S Paramothayan; T J Lasserson; A U Wells; E H Walters
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

5.  The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

Review 6.  Drug treatment of pulmonary arterial hypertension: current and future agents.

Authors:  Marius M Hoeper
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  New approaches to the treatment of pulmonary hypertension: from bench to bedside.

Authors:  Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

8.  Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedullin.

Authors:  Jacob Kach; Nathan Sandbo; Nan Sethakorn; Jesse Williams; Eleanor B Reed; Jennifer La; Xinyong Tian; Susan D Brain; Kavitha Rajendran; Ramaswamy Krishnan; Anne I Sperling; Konstantin Birukov; Nickolai O Dulin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-12       Impact factor: 5.464

9.  Influence of Rho kinase inhibitor Fasudil on late endothelial progenitor cells in peripheral blood of COPD patients with pulmonary artery hypertension.

Authors:  Pei Liu; Hongmei Zhang; Yijun Tang; Chunfeng Sheng; Jianxin Liu; Yanjun Zeng
Journal:  Bosn J Basic Med Sci       Date:  2014-02       Impact factor: 3.363

10.  Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Mariko Harada-Shiba; Itaru Takamisawa; Kanjiro Miyata; Takehiko Ishii; Nobuhiro Nishiyama; Keiji Itaka; Kenji Kangawa; Fumiki Yoshihara; Yujiro Asada; Kinta Hatakeyama; Noriya Nagaya; Kazunori Kataoka
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.